Affiliation:
1. Pharmacogenomics Lab., Department of Biosciences, Barkatullah University, Bhopal (MP) 462026, India
2. Department of Zoology, Government P.G. College, BHEL, Bhopal (MP) 462022, India
3. Clinical Pharmacognosy Lab., Department of Pharmacy Practice, PAHO, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, United States
Abstract
Background:
Leukotrienes are powerful mediators of inflammation and interact with specific
receptors in target cell membrane to initiate an inflammatory response. Thus, Leukotrienes (LTs)
are considered to be potent mediators of inflammatory diseases including allergic rhinitis, inflammatory
bowel disease and asthma. Leukotriene B4 and the series of cysteinyl leukotrienes (C4, D4, and E4) are
metabolites of arachidonic acid metabolism that cause inflammation. The cysteinyl LTs are known to
increase vascular permeability, bronco-constriction and mucus secretion.
Objectives:
To review the published data for leukotriene inhibitors of plant origin and the recent patents
for leukotriene inhibitors, as well as their role in the management of inflammatory diseases.
Methods:
Published data for leukotrienes antagonists of plant origin were searched from 1938 to 2019,
without language restrictions using relevant keywords in both free text and Medical Subject Headings
(MeSH terms) format. Literature and patent searches in the field of leukotriene inhibitors were carried
out by using numerous scientific databases including Science Direct, PubMed, MEDLINE, Google
Patents, US Patents, US Patent Applications, Abstract of Japan, German Patents, European Patents,
WIPO and NAPRALERT. Finally, data from these information resources were analyzed and reported
in the present study.
Results:
Currently, numerous anti-histaminic medicines are available including chloropheneremine,
brompheniramine, cetirizine, and clementine. Furthermore, specific leukotriene antagonists from allopathic
medicines are also available including zileuton, montelukast, pranlukast and zafirlukast and are
considered effective and safe medicines as compared to the first generation medicines. The present
study reports leukotrienes antagonistic agents of natural products and certain recent patents that could
be an alternative medicine in the management of inflammation in respiratory diseases.
Conclusion:
The present study highlights recent updates on the pharmacology and patents on leukotriene
antagonists in the management of inflammation respiratory diseases.
Funder
Madhya Pradesh Council of Science and Technology,Govt. of Madhya Pradesh
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,General Medicine,Immunology and Allergy
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Innate immunity response of zafirlukast treated-tilapia during foreign body inflammation;Developmental & Comparative Immunology;2024-04
2. Design, Synthesis, Biological Evaluation, and Molecular Docking Study of 4,6-Dimethyl-5-aryl/alkyl-2-[2-hydroxy-3-(4-substituted-1-piperazinyl)propyl]pyrrolo[3,4-c]pyrrole-1,3(2H,5H)-diones as Anti-Inflammatory Agents with Dual Inhibition of COX and LOX;Pharmaceuticals;2023-05-29
3. Phospholipase signaling in inflammation and promiscuity of phospholipase active site ligands;Phospholipases in Physiology and Pathology;2023
4. Increased expressions of CD123, CD63, CD203c, and Fc epsilon receptor I on blood leukocytes of allergic asthma;Frontiers in Molecular Biosciences;2022-08-11
5. Novel aerosol treatment of airway hyper-reactivity and inflammation in a murine model of asthma with a soluble epoxide hydrolase inhibitor;PLOS ONE;2022-04-20